tetano
Editor, Senior Moderator
Cell. 2020 Apr 29. pii: S0092-8674(20)30483-9. doi: 10.1016/j.cell.2020.04.020. [Epub ahead of print]
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR[SUP]1[/SUP], Dhamdhere G[SUP]2[/SUP], Liu Y[SUP]1[/SUP], Lin X[SUP]1[/SUP], Goudy L[SUP]1[/SUP], Zeng L[SUP]1[/SUP], Chemparathy A[SUP]3[/SUP], Chmura S[SUP]4[/SUP], Heaton NS[SUP]5[/SUP], Debs R[SUP]4[/SUP], Pande T[SUP]6[/SUP], Endy D[SUP]1[/SUP], La Russa MF[SUP]7[/SUP], Lewis DB[SUP]8[/SUP], Qi LS[SUP]9[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.
Copyright ? 2020 Elsevier Inc. All rights reserved.
KEYWORDS:
2019-nCoV; COVID-19; CRISPR; Cas13; IAV; RdRP; SARS-CoV-2; antiviral; influenza; nucleocapsid
PMID:32353252DOI:10.1016/j.cell.2020.04.020
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Abbott TR[SUP]1[/SUP], Dhamdhere G[SUP]2[/SUP], Liu Y[SUP]1[/SUP], Lin X[SUP]1[/SUP], Goudy L[SUP]1[/SUP], Zeng L[SUP]1[/SUP], Chemparathy A[SUP]3[/SUP], Chmura S[SUP]4[/SUP], Heaton NS[SUP]5[/SUP], Debs R[SUP]4[/SUP], Pande T[SUP]6[/SUP], Endy D[SUP]1[/SUP], La Russa MF[SUP]7[/SUP], Lewis DB[SUP]8[/SUP], Qi LS[SUP]9[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.
Copyright ? 2020 Elsevier Inc. All rights reserved.
KEYWORDS:
2019-nCoV; COVID-19; CRISPR; Cas13; IAV; RdRP; SARS-CoV-2; antiviral; influenza; nucleocapsid
PMID:32353252DOI:10.1016/j.cell.2020.04.020